Top
Artemis-deficient-SCID - Healing Genes
622
post-template-default,single,single-post,postid-622,single-format-standard,mkdf-bmi-calculator-1.0,mkd-core-1.1.1,tribe-no-js,wellspring-ver-1.8,mkdf-smooth-page-transitions,mkdf-ajax,mkdf-grid-1300,mkdf-blog-installed,mkdf-header-standard,mkdf-no-behavior,mkdf-default-mobile-header,mkdf-sticky-up-mobile-header,mkdf-dropdown-slide-from-bottom,mkdf-full-width-wide-menu,mkdf-search-dropdown,elementor-default,elementor-template-full-width,elementor-kit-3486,elementor-page-2540

Artemis-deficient-SCID

Share This Post

Share on facebook
Share on linkedin
Share on twitter
Share on email

Autologous Gene Therapy for Artemis-Deficient SCID

A Phase I/II Feasibility Study of Gene Transfer for Artemis-Deficient Severe Combined Immunodeficiency (ART-SCID) Using a Self-Inactivating Lentiviral Vector (AProArt) to Transduce Autologous CD34 Hematopoietic Cells


Phase 1/2

DESCRIPTION:

Doctors seek patients 2 months of age and older with artemis-deficient Severe Combined Immunodeficiency (ART-SCID) caused by mutations in the DCLRE1C gene. Researchers will withdraw stem cells, gene-modify them to deliver a normal copy of the DCLRE1C gene, and return them to the patient after a low dose of chemotherapy. It is hoped this will provide the patients with a normal immune system.

Study participants will undergo a blood draw treatment that sorts out specific cells and returns the blood to the patient. After the gene modification in the lab, the cells are infused post chemotherapy and the patient will be closely assessed for 1 month, will follow up required at 42 days, 1 year, 2 years, and up to 15 years.


PATIENT MUST:

  • Be 2 months of age or older
  • Have a diagnosis of typical or leaky ART-SCID
  • Meet lab assessments for minimal levels of the type of immune cells targeted by the gene therapy
  • Not be pregnant or HIV-positive

THE STUDY INVOLVES:

  1. Screening before the treatment
  2. Blood apheresis using the CliniMACS system will draw the needed immune cells but return blood cells to the body
  3. Researchers will use a virus in the lab to deliver the gene to the immune cells
  4. A low dose of chemotherapy will be delivered
  5. The gene-modified immune cells will be re-infused to the patient
  6. The patient will be closely assessed for 1 month, will follow up required at 42 days, 1 year, 2 years, and up to 15 years.

LOCATIONS AND CONTACTS:

Trials will take place at the University of California, San Francisco Children’s Hospital. Map.

Contact: Morton Cowan, MD  |  [email protected]  | 415-476-2188

Contact: Jennifer Puck, MD  |  [email protected]  | 415 502-2090

 

SPONSOR INFORMATION:

University of California, San Francisco

 

Or go online:

https://clinicaltrials.gov/ct2/show/NCT03538899

Subscribe To Our Newsletter

Get updates and learn from the best

More To Explore

Vanquishing the Virus: 160+ COVID-19 Drug and Vaccine Candidates in Development

While President Trump continues to promote antimalarial drugs such as hydroxychloroquine sulfate and azithromycin to treat COVID-19—“What do you have to lose?” he exclaimed during the April 4 Coronavirus Task Force Briefing—the global community of drug discovery researchers and biopharmas is developing a much broader